Inhibitory Antibodies

MCE Inhibitory Antibodies are monoclonal antibodies (mAbs) that have been extensively used in the hottest research areas, such as cancer, immunology and infection. These monoclonal antibodies (mAbs) bind monospecifically to certain cells or proteins, thus stimulating the immune system to attack the malignant tumor cells and preventing tumor growth by blocking specific cell receptors. They can inhibit PD-1, PD-L1, EGFR, VEGFR, TNF-alpha or other targets which are unusually active in diseases, such as non-Hodgkin lymphoma, Hemophilia A, renal cell carcinoma, Parkinson's disease and metastatic HER2-positive breast cancer. For example, by binding to VEGF, Bevacizumab prevents VEGF from interacting with its receptors, thereby inhibiting new vessel growth. Lambrolizumab targets the programmed cell death 1 (PD-1) receptor of lymphocytes. By preventing the binding of its ligands (PD-L1 and PD-L2), Lambrolizumab induces an antitumor immune response.

Abatacept
(CTLA4Ig; BMS-188667) Cat. No.: HY-108829

Abatacept (CTLA4Ig) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein drug for the autoimmune diseases.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Adalimumab
(Anti-Human TNF-alpha, Human Antibody) Cat. No.: HY-P9908

Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factorα (**TNF-α**).



Purity: 98.12%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 25 mg, 50 mg

Anti-MERS-2E6 mAb
(MERS-2E6; MERS Antibody-2E6) Cat. No.: HY-P9804

Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (**CD26**), thereby inhibiting **virus** invasion into host cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-MERS-3A1 mAb
(MERS-3A1; MERS Antibody-3A1) Cat. No.: HY-P9805

Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-MERS-D12 mAb
(MERS-D12; MERS Antibody-D12) Cat. No.: HY-P9806

Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-SARS-80R mAb
(SARS-80R; SARS Antibody-80R) Cat. No.: HY-P9803

Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to **Spike (S1)** protein to prevent **SARS** virus infection of susceptible cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-SARS-CoV-2 Spike mAb (CR3022)
(SARS-CR3022; SARS-CoV-2 Antibody-CR3022) Cat. No.: HY-P9807

Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein.

Purity: 95.00%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-Spike-RBD mAb
(SARS-CoV-2 (2019-nCoV) Spike RBD Antibody) Cat. No.: HY-P9801

Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Anti-Spike-RBD Single Domain mAb (SARS-CoV-2 (2019-nCoV)
Single-Domain Antibodies; ...) Cat. No.: HY-P9802

Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Atezolizumab
(MPDL3280A) Cat. No.: HY-P9904

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (**PD-L1**), used for cancer research.

Purity: 98.98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Avelumab (Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C)

Cat. No.: HY-108730

Avelumab is a fully human IgG1 anti-**PD-L1** monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

Avelumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Benralizumab (MEDI-563; BIW-8405)

Cat. No.: HY-P9923

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity.

Benralizumab

Purity: ≥99.1%
Clinical Data: Launched
Size: 1 mg, 2 mg

Bevacizumab (Anti-Human VEGF, Humanized Antibody)

Cat. No.: HY-P9906

Bevacizumab, a humanized monoclonal antibody, specifically binds to all **VEGF-A** isoforms with high affinity.

Bevacizumab

Purity: 98.50%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Camrelizumab (SHR-1210)

Cat. No.: HY-P9971

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to **PD-1**. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC_{50} of 0.70 nM.

Camrelizumab

Purity: 97.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cetuximab (C225)

Cat. No.: HY-P9905

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (**EGFR**), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Cetuximab

Purity: 99.70%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Daratumumab (Anti-Human CD38, Human Antibody)

Cat. No.: HY-P9915

Daratumumab (Anti-Human CD38) is the first-in-class human-specific **anti-CD38** monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Daratumumab

Purity: 98.70%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dupilumab (REGN-668; SAR-231893)

Cat. No.: HY-P9926

Dupilumab (REGN-668) is a fully human mAb to **IL-4 receptor α (IL-4Rα)** that inhibits both **IL-4** and **IL-13** signaling, markedly improved moderate-to-severe atopic dermatitis.

Dupilumab

Purity: ≥99.20%
Clinical Data: Launched
Size: 1 mg, 5 mg

Durvalumab (MEDI 4736)

Cat. No.: HY-P9919

Durvalumab (MEDI 4736) is an humanized anti-**PD-L1** monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of **PD-L1** to both **PD-1** and **CD80**, with IC_{50}s of 0.1 and 0.04 nM, respectively.

Durvalumab

Purity: 99.60%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Etanercept

Cat. No.: HY-108847

Etanercept, a dimeric fusion protein that binds TNF, acts as a **TNF** inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive.

Etanercept

Purity: ≥96.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Infliximab (Avakine; CT-P13)

Cat. No.: HY-P9970

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to **TNF-α**. Infliximab prevents the interaction of **TNF-α** with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.

Avakine

Purity: 90.30%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

Ipilimumab

(MDX-010; BMS-734016)

Cat. No.: HY-P9901

Ipilimumab is a fully human monoclonal IgG1κ antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune-inhibitory molecule expressed in activated T cells and in suppressor T regulatory cells.

Ipilimumab

Purity: 99.88%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Natalizumab

Cat. No.: HY-108831

Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-**integrin** and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Natalizumab

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 25 mg

Nimotuzumab

Cat. No.: HY-P9968

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting **EGFR** with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands.

Nimotuzumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nivolumab

(BMS-936558; ONO-4538; MDX-1106)

Cat. No.: HY-P9903

Nivolumab is a programmed death receptor-1 (**PD-1**) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.

Nivolumab

Purity: 98.56%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Obinutuzumab

(GA101; Anti-Human CD20 type II, Humanized Antibody)

Cat. No.: HY-P9910

Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Obinutuzumab

Purity: ≥99.4%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Omalizumab

(Olizumab; rhuMab-E25)

Cat. No.: HY-P9950

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.

Olizumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pembrolizumab

(MK-3475; Lambrolizumab)

Cat. No.: HY-P9902

Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (**PD-1**) receptor, used in cancer immunotherapy.

Pembrolizumab

Purity: 99.06%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Pertuzumab

Cat. No.: HY-P9912

Pertuzumab, a humanized monoclonal antibody, is a **HER2** dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

Pertuzumab

Purity: ≥99.1%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Raleukin

(AMG-719)

Cat. No.: HY-108841

Raleukin (AMG-719) is a recombinant, nonglycosylated human **interleukin-1 receptor (IL-1R)** antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects.

Raleukin

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg

Ramucirumab

Cat. No.: HY-P9920

Ramucirumab is a human **VEGFR-2** antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.

Ramucirumab

Purity: 99.40%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Ranibizumab

(RG-6321) Cat. No.: HY-P9951

Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research.

Ranibizumab

Purity: 98.60%
Clinical Data: Launched
Size: 1 mg

Reslizumab

(Sch 55700) Cat. No.: HY-P9949

Reslizumab (Sch 55700) is humanized monoclonal antibodies that target **interleukin-5 (IL-5)** for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of **IL-5**.

Reslizumab

Purity: ≥99.4%
Clinical Data: Launched
Size: 1 mg, 2 mg

Rituximab

(Anti-Human CD20 type I, Chimeric Antibody) Cat. No.: HY-P9913

Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

Rituximab

Purity: 99.85%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Sarilumab

(Anti-Human IL6Rα, Human Antibody) Cat. No.: HY-P9916

Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a **interleukin-6 (IL-6) receptor** antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation.

Sarilumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Seletracetam lithium

(Ucb 44212 lithium) Cat. No.: HY-119810A

Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a **SV2A** modulator for the research of epilepsy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tocilizumab

(Anti-Human IL6R, Humanized Antibody) Cat. No.: HY-P9917

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (**IL-6R**) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling.

Tocilizumab

Purity: 99.67%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

Trastuzumab

(Anti-Human HER2, Humanized Antibody) Cat. No.: HY-P9907

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

Trastuzumab

Purity: 99.80%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Trastuzumab emtansine

(Ado-Trastuzumab emtansine; PRO132365; T-DM 1) Cat. No.: HY-P9921

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).

Trastuzumab emtansine

Purity: ≥99.40%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Ustekinumab

(Anti-Human IL-12/IL-23, Human Antibody) Cat. No.: HY-P9909

Ustekinumab is an anti-**IL-12/IL-23** IgG1κ human monoclonal antibody.

Ustekinumab

Purity: 98.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 25 mg, 50 mg

Vedolizumab

(Anti-Human lymphocyte α4β7 integrin, Humanized Antibody) Cat. No.: HY-P9911

Vedolizumab is a humanized monoclonal antibody that targets the α4β7 **integrin** for the treatment of ulcerative colitis and Crohn's disease.

Vedolizumab

Purity: 99.64%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg